Controlled propagation of replication-competent Sindbis viral vector using suicide gene strategy
J-C Tseng1, G Daniels, D Meruelo
1NYU Cancer Institute and the NYU Gene Therapy Center, Department of Pathology, NYU School of Medicine, New York University, New York, NY 10016, USA.
Gene Therapy
|September 27, 2008
Summary
This study introduces a novel replication-competent Sindbis virus vector for gene therapy. This enhanced vector improves tumor targeting and killing, while a suicide gene provides a crucial safety mechanism against uncontrolled spread.
Area of Science:
- Virology
- Gene Therapy
- Oncology
Background:
- Viral gene therapy faces safety concerns due to uncontrolled vector spread.
- Replication-defective vectors enhance safety but reduce therapeutic efficacy.
- Previous work demonstrated effective tumor targeting with replication-defective Sindbis vectors.
Purpose of the Study:
- To develop a safer and more potent viral gene therapy vector.
- To engineer a replication-competent Sindbis virus with a built-in safety switch.
- To evaluate the efficacy and safety of the novel vector in tumor treatment.
Main Methods:
- Construction of a replication-competent Sindbis viral vector with an incorporated HSV-TK suicide gene.
- In vivo evaluation of tumor targeting and growth suppression.
- Assessment of the safety mechanism using a prodrug (ganciclovir).
Main Results:
- The replication-competent vector demonstrated enhanced tumor-specific infection and growth suppression compared to replication-defective vectors.
- The HSV-TK suicide gene, activated by ganciclovir, effectively controlled vector propagation.
- Prodrug-activated toxic metabolites contributed to bystander killing of neighboring tumor cells.
Conclusions:
- A replication-competent Sindbis vector with a suicide gene offers improved therapeutic potency and safety for gene therapy.
- This dual-action strategy enhances tumor killing while mitigating risks of uncontrolled viral spread.
- The engineered vector shows significant promise for effective cancer treatment through targeted gene delivery and enhanced oncolysis.
